Scilex Acquires ACEA Pharma for $1 Billion

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 5 days ago

0mins

PHOE+26.23%

SCLX-2.74%

Should l Buy PHOE?

Source: Newsfilter

Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PHOE?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PHOE

About PHOE

Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal

5 days agostocktwits

Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.